AAM Sawgrass US Small Cap Quality Growth ETF
SAWS - ETF AI Analysis
Top Page
AAM Sawgrass US Small Cap Quality Growth ETF (SAWS)
SAWS, the AAM Sawgrass US Small Cap Quality Growth ETF, earns a solid overall rating thanks to several strong growth-focused holdings like Iradimed, Mueller Industries, CareDx, Digi International, and Gorman-Rupp, which show robust financial performance, positive earnings sentiment, and generally supportive technical trends. However, more leveraged and operationally challenged names such as Guardian Pharmacy Services and StoneX Group, along with some holdings facing high valuations and overbought conditions, slightly temper the fund’s appeal and highlight risks around financial leverage and potential short-term volatility.
SAWS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.94M
- Region
- North America
- Expense Ratio
- 0.55%
- Beta
- 0.80
- Issuer
- AAM
- Inception Date
- Jul 30, 2024
- Dividend Yield
- 0.02%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
SAWS Summary
SAWS is the AAM Sawgrass US Small Cap Quality Growth ETF, focused on smaller U.S. companies that aim for strong, long-term growth rather than following a specific index. It invests across many sectors, including health care, industrials, and technology, and holds companies like Pricesmart and Sanmina-Sci. Someone might consider SAWS to add diversification and growth potential from up-and-coming businesses that are not yet large household names. However, because it invests in small companies, the share price can be more volatile and may go up and down more sharply than funds focused on larger, more established firms.
How much will it cost me?
This ETF has an expense ratio of 0.55%, which means you’ll pay about $5.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, focusing on a specialized group of small-cap growth companies rather than simply tracking a broad market index.
What would affect this ETF?
Future performance of SAWS will benefit if the U.S. economy stays healthy, supporting small, fast-growing companies in sectors like health care, industrials, and technology, and if innovation and demand for medical and tech solutions remain strong. On the downside, rising interest rates, an economic slowdown in the U.S., or tighter regulations in health care and financial services could hurt small-cap growth stocks and make this ETF more volatile.
SAWS Top 10 Holdings
SAWS is leaning heavily into U.S. small-cap health care and tech, and that’s where most of the action is. CareDx has been a standout, rising sharply and giving the fund a strong growth engine, while Bioventus and Digi International add more steady-to-rising momentum on the innovation side. On the flip side, Iradimed and Mueller Industries have been lagging, acting like a bit of sand in the gears. With all holdings U.S.-based and several health care names near the top, the ETF is clearly betting on domestic, high-growth medical and tech stories.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| BrightSpring Health Services, Inc. | 3.64% | $252.57K | $14.22B | 124.28% | 67Neutral | |
| Pricesmart | 3.13% | $217.12K | $5.09B | 41.91% | 77Outperform | |
| StoneX Group | 3.05% | $211.30K | $6.89B | 44.86% | 58Neutral | |
| Pattern Group, Inc. Class A | 2.71% | $188.15K | $3.70B | 14.75% | ―― | |
| Digi International | 2.59% | $179.45K | $2.22B | 43.86% | 77Outperform | |
| Agilon Health | 2.54% | $176.12K | $1.85B | 667.99% | 42Neutral | |
| Oscar Health | 2.40% | $166.39K | $9.86B | 122.58% | 49Neutral | |
| Gorman-Rupp Company | 2.49% | $172.44K | $1.85B | 52.50% | 76Outperform | |
| CareDx | 2.36% | $163.56K | $4.19B | 390.74% | 77Outperform | |
| Lifestance Health Group | 2.15% | $149.19K | $5.38B | 123.14% | 61Neutral |
SAWS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SAWS, the sentiment is Negative. The current price of 22.05 is below the 20-day moving average (MA) of 22.19, below the 50-day MA of 22.67, and below the 200-day MA of 23.22, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 45.44 is Neutral, neither overbought nor oversold. The STOCH value of 74.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SAWS.
SAWS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $22.05 | $23.00(4.31% Upside) | $6.94M | 0.55% | 68Neutral | |
| $45.91 | $62.62(36.40% Upside) | $52.99M | 0.49% | 64Neutral | |
| $34.54 | $43.57(26.16% Upside) | $52.83M | 0.85% | 63Neutral | |
| $26.19 | $33.35(27.34% Upside) | $52.26M | 0.95% | 63Neutral | |
| $24.67 | $35.15(42.52% Upside) | $27.93M | 0.80% | 60Neutral | |
| $25.77 | $35.49(37.72% Upside) | $7.91M | 0.28% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SAWS | AAM Sawgrass US Small Cap Quality Growth ETF | 22.05 | 1.95 | 9.70% | |
| ACSG | American Century Small Cap Growth Insights ETF | 45.91 | 7.10 | 18.28% | |
| TMFS | Motley Fool Small-Cap Growth ETF | 34.54 | 1.81 | 5.52% | |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 26.19 | 3.60 | 15.94% | |
| SGRW | Harbor Active Small Cap Growth ETF | 24.67 | 4.37 | 21.55% | |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 25.77 | 0.54 | 2.14% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
